Although glucagon dysregulation is as important as insulin dysregulation in type 2 diabetes, therapeutic pharmacological approaches targeting glucagon are lacking [11,12], compared with pharmacological approaches that improve insulin secretion and β-cell function [13,14]. Here, INS is linked to type 2 diabetes mellitus.